Mythic Therapeutics
Mythic Therapeutics was an oncology biotech developing antibody-drug conjugates designed to deliver cancer treatments more selectively to tumors.
The Story
Mythic Therapeutics was founded in 2017 around a promising idea in cancer medicine.
Antibody-drug conjugates, or ADCs, attempt to combine the targeting ability of antibodies with powerful cancer-killing drugs.
The challenge is delivery.
If the drug reaches healthy tissue as well as tumors, toxicity can become a major limitation.
Mythic developed what it called its Dolaflexin-based ADC technology and attempted to create therapies capable of delivering cancer drugs more selectively.
The company attracted substantial investment.
Its 2021 Series B alone brought in $103 million.
That funding allowed Mythic to advance its lead program, MYTX-011, into clinical development.
The company was targeting difficult cancers, including non-small-cell lung cancer.
But biotech has a dangerous financial structure.
A company can spend hundreds of millions of dollars developing a therapy and still have no commercial product.
The next financing round depends heavily on clinical data.
If the data are promising, investors may fund another stage.
The Turning Point
If the data are ambiguous or the capital market turns hostile, the company can become trapped.
That is what happened to Mythic.
In 2025, the biotech sector was still dealing with a difficult financing environment, particularly for companies without late-stage clinical assets.
Mythic carried out layoffs and attempted to raise additional capital.
It was unsuccessful.
In December 2025, the company terminated its sole clinical trial and began winding down.
Its remaining assets were put up for sale.
The failure therefore wasn't simply a case of the science being disproven.
The company's lead program had reached clinical development, but Mythic could not secure the financing needed to continue.
That distinction is important.
In biotech, a company can die before its scientific thesis is conclusively proven wrong.
The capital required to reach the next milestone can disappear before the science has enough time to mature.
Timeline
Funding
Mythic Therapeutics raised $103M+ in total capital across its operating history. Operating for 8 years in the Biotechnology / Oncology sector in United States, capital intensity and runway constraints played a defining role in its closure.
Why It Failed
Unable to secure additional funding; clinical program terminated
When the primary growth hypothesis or strategic acquisition discussions stalled, the business lacked the financial buffer to pivot or restructure on its own terms.
Operating in Biotechnology / Oncology created structural dependencies that left no room for extended clinical, distribution, or revenue delays.
Lessons for Builders
“Biotech startups don't just need enough money to discover a drug. They need enough money to survive every financing milestone between discovery and proof.”
- Endpoints News — Mythic Therapeutics shutdown
- Fierce Biotech — Mythic wind-down
- Mythic Therapeutics — company research and clinical development history